In a new filing with the SEC, Cambridge, MA’s Archemix set terms for its IPO of 4.5 million shares at $12 to $14 per share. The firm, which plans to trade on the NASDAQ Global Market under the symbol “ARCH,” is developing “aptamers,” or short strands of DNA or RNA, as treatments for a variety of ailments.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
